- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli | ||
| Mi | Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs | ||
| Mi | Epicrispr, Vaderis secure pivotal study funding for rare disease assets | ||
| Mi | Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat | ||
| Mi | Alfasigma signs agreement to acquire Nordic Group | ||
| Di | Trump signs order that nearly halves childhood immunisation coverage | ||
| Di | UK regulators greenlight Lilly's Foundayo, intensifying Novo competition | ||
| Di | BMS banks on Texas for $2.3bn multi-modal manufacturing facility | ||
| Di | BeOne and Revolution Medicines partner for oncology therapies | ||
| Di | Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront | ||
| Mo | Sobi licenses Innate's CTCL drug for up to $580m as it heads to Phase III | ||
| Mo | Innovent and Daiichi Sankyo sign deal for Vanflyta in China | ||
| Mo | Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs | ||
| Fr | Tarsus joins Stargardt race to market with $800m Alkeus takeover | ||
| Fr | Context drops bispecific T-cell engager on cost-cutting initiative | ||
| Fr | Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations | ||
| Fr | Evotec and Odyssey collaborate on AI-enabled R&D | ||
| Fr | Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments | ||
| 06.08. | Takeda nets first-in-class advantage on narcolepsy drug's FDA go-ahead | ||
| 06.08. | Eli Lilly raises 2026 outlook again as Q2 soars past estimates | ||
| 06.08. | Alteogen signs $365m Hybrozyme licensing deal with pharma company | ||
| 06.08. | Schrödinger and BMS expand partnership to deploy AI for drug discovery | ||
| 05.08. | Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says | ||
| 05.08. | What is 'Premium Content' on Pharmaceutical Technology? | ||
| 05.08. | Mironid banks $46m in Series B to take rare kidney disease drug closer to clinic |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.